Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential CONSULTING AGREEMENTConsulting Agreement • November 10th, 2021 • Precision Biosciences Inc • Biological products, (no disgnostic substances) • North Carolina
This CONSULTING AGREEMENT (“Agreement”) is made by and between Precision BioSciences, Inc., a Delaware corporation having a place of business at 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC 27701 (“Company”), and Dr. David Thomson, an individual having an address at [***] as of July 2, 2021 (the “Effective Date”).
FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 10th, 2021 • Precision Biosciences Inc • Biological products, (no disgnostic substances)
This First Amendment to Development and License Agreement (“First Amendment”) is entered into as of August 9, 2021 (the “First Amendment Effective Date”) by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having an address at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, U.S.A. (“Precision”), and Eli Lilly and Company, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (“Lilly”). Lilly and Precision are each hereafter referred to individually as a “Party” and together as the “Parties.”
